Novel vaccines for emerging pathogens like Norovirus and *Clostridioides difficile* (C. difficile) are increasingly important due to their significant public health impact. Norovirus is a leading cause of viral gastroenteritis worldwide, responsible for severe outbreaks in healthcare settings, cruise ships, and schools. It spreads rapidly, causes substantial illness, and currently lacks a licensed vaccine. *C. difficile* is a major cause of healthcare-associated infections, often following antibiotic use, leading to life-threatening diarrhea and colitis, especially in older adults.
As antibiotic resistance rises and global travel increases the spread of infectious diseases, effective vaccines offer a preventive solution to reduce transmission, morbidity, and healthcare costs. They can protect vulnerable populations, such as the elderly and immunocompromised, and reduce the burden on healthcare systems. Investing in vaccines for these pathogens is a proactive approach to future-proof global health, especially in an era where emerging infections pose growing threats to public safety.
